Related Experiment Video
Updated: Aug 4, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Captopril in the treatment of congestive heart failure
1Cardiology Research, Washington Adventist Hospital, Takoma Park, Maryland.
Insights
Captopril, an angiotensin-converting enzyme (ACE) inhibitor, offers significant benefits for heart failure patients, improving symptoms, exercise capacity, and survival rates compared to traditional treatments.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) traditionally managed with digoxin and diuretics.
- Vasodilators often serve as supplementary therapy for symptomatic patients.
- Angiotensin-converting enzyme (ACE) inhibitors represent a significant advancement in CHF treatment.
Purpose of the Study:
- To review the clinical use and benefits of captopril, an ACE inhibitor.
- To highlight captopril's superiority over standard CHF treatments.
- To discuss captopril's impact on heart failure survival rates.
Main Methods:
- Review of controlled studies on ACE inhibitors, specifically captopril.
- Analysis of captopril's effects on hemodynamics, exercise capacity, and metabolic derangements.
- Examination of clinical guidelines for captopril initiation and dosage.
Main Results:
- Captopril reduces symptoms and improves hemodynamics and exercise capacity in CHF patients.
- It favorably impacts metabolic issues like fluid retention and electrolyte imbalances.
- Most notably, captopril is associated with improved survival rates in heart failure.
Conclusions:
- Captopril offers substantial clinical benefits for heart failure management.
- Dosage adjustments are recommended prior to initiating captopril, especially in volume-contracted patients.
- Captopril demonstrates superiority to other vasodilators and is effective in mild CHF cases.
Abstract:
This 3-part discussion of captopril, the first oral angiotensin converting enzyme (ACE) inhibitor, focuses on the clinical use and superiority of this agent to standard treatments and the new observations that use can improve the overall poor survival associated with heart failure. Today, as in the past, treatment of CHF includes digoxin and diuretics. Vasodilators have been relegated by some to the role of supplementing therapeutic regimens when patients remain symptomatic. Recently, controlled studies have shown that the introduction and supplementation of therapeutic regimens with ACE inhibitions and specifically captopril is associated with substantial clinical benefits: Symptoms are reduced as hemodynamics and exercise capacity improve, metabolic derangements (including fluid retention, potassium and magnesium loss and sympathetic nervous activation) are reduced with resultant favourable effects on arrhythmia frequency and finally the newest and most dramatic observation of improved survival. This review will briefly summarize these developments and assist in the clinically important aspects of this therapy for practicing physicians. Guidelines for the clinical use of captopril: In patients with confirmed dilated cardiomyopathy, captopril improves stroke volume in response to afterload reduction, but in volume-contracted patients vasodilation may be associated with hypotension. Therefore, prior to initiating captopril, the diuretic dosage should be reduced, particularly in low serum sodium concentration states if intravascular volume is depleted. Potassium supplements should be stopped due to the expected decrease of aldosterone production and improved potassium retention. Initial therapy should be started with a low captopril dosage (2 to 3 times 6.25 mg/day), maintenance dosages are 25 or 50 mg b.i.d. or t.i.d. Superiority to other vasodilator drugs and use in mild cases: In studies of acute and chronic CHF, captopril improves hemodynamics, exercise tolerance, and reduces symptoms.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies

